C. Chang

FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Pazdur, A. Al-Hakim, R. Justice, 2015, Clinical Cancer Research.

A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer

J. Marshall, J. Posey, Jimmy J. Hwang, 2007 .

Adjuvant nitrosourea therapy for glioblastoma.

E. Housepian, R. Brisman, C. Chang, 1976, Archives of neurology.

Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial

J. Bruix, P. Galle, R. Finn, 2017, Zeitschrift für Gastroenterologie.

Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial

J. Bruix, O. Yokosuka, G. Bodoky, 2017, Zeitschrift für Gastroenterologie - German Journal of Gastroenterology.

FDA Approval Summary: Margetuximab plus chemotherapy for advanced or metastatic HER2-positive breast cancer.

R. Pazdur, R. Charlab, B. King-Kallimanis, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.